Search
Searching Goglides
Loading matching companies, research, topics, and discussions.
Searching Goglides
Loading matching companies, research, topics, and discussions.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Showing public results only.
SEC filings, financial facts, source resources, and Goglides workspace context for IonQ, Inc..
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
Q1 2026 revenue beat, raised revenue guidance, and the first sixth-generation 256-qubit system sale. The proof gate is RPO conversion, organic revenue growth, and adjusted EBITDA loss discipline.
OpenIonQ reported 2025 revenue of $130.0 million, a $633.7 million operating loss and $1.03 billion of cash at year end. The thesis is not whether quantum computing is exciting; it is whether IonQ can turn a large cash position and technical roadmap into durable c
OpenRubrik reported FY2026 revenue of $1.3 billion, FY2026 operating cash flow of $282.9 million, a FY2026 net loss of $348.8 million and $380.2 million of cash. The thesis depends on subscription durability, data security demand, operating leverage, cash conversi
OpenIonQ needs to prove its quantum advantage can survive competition from larger tech platforms with deeper budgets.
OpenIonQ benefits from quantum-computing excitement, but investors need to separate scientific progress from commercial revenue.
OpenCrowdStrike is a premium cybersecurity platform with strong ARR and cash-flow evidence, but the sharper risk is valuation-liquidity sensitivity around catalysts, not a proven hidden lock-up squeeze.
OpenAgios has FDA-approved mitapivat products, an early AQVESME thalassemia launch and more than $1.0B of cash and marketable securities. The diligence question is whether prescription growth and pipeline catalysts can outpace a quarterly expense base above $130M.
OpenACAD is no longer the kind of biotech where everything hangs on a single trial. The sharper question is whether NUPLAZID and DAYBUE can fund a third CNS franchise before concentration, payer pressure, and pipeline risk catch up.
OpenAlpha Cognition has an FDA-approved Alzheimer's pill, early long-term-care launch traction, two PBM agreements, and $66.0 million of year-end cash, but the story depends on ZUNVEYL turning bottle growth into repeat, reimbursed revenue before launch spending, s
OpenTag facets appear after tag usage counts are rebuilt.